Pooja Shah, Ayyanraj Neeravi, Rajiv Karthik, Christy Merin Mathew, Julie Hephzibah, Hanna Elizabeth Johnson, Balaji Veeraraghavan, Abi Manesh
{"title":"Successful use of cefepime/zidebactam in deep-seated infections due to extensively drug-resistant Pseudomonas aeruginosa - a case series.","authors":"Pooja Shah, Ayyanraj Neeravi, Rajiv Karthik, Christy Merin Mathew, Julie Hephzibah, Hanna Elizabeth Johnson, Balaji Veeraraghavan, Abi Manesh","doi":"10.1016/j.jgar.2025.07.009","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is a paucity of safe and effective treatment options for extensively drug resistant (XDR) Gram-negative pathogens that often harbor varied resistance mechanisms concurrently. Cefepime/zidebactam (FEP/ZID) is a novel β-lactam/β-lactam enhancer (BL-BLE) combination, currently in Phase 3 trials, that has been shown to be effective against such difficult to treat resistant isolates in in-vitro studies and scattered case reports. We present a series of deep seated infections due to XDR Pseudomonas Aeruginosa (PsA), successfully treated with FEP/ZID under compassionate use.</p><p><strong>Method: </strong>Between September 2023 and May 2024, using clinico-radiographic and microbiologic (phenotypic drug susceptibility and whole genome sequencing) data, we identified five XDR PsA related infections that could not be safely treated with currently available antibiotics. All patients received FEP/ZID after obtaining informed consent and necessary approvals.</p><p><strong>Results: </strong>Four cases involved osteoarticular disease while the fifth was an endovascular graft infection. Clinical specimens yielded XDR PsA isolates that harbored varied (enzymatic and non-enzymatic) resistance mechanisms to anti-pseudomonal cephalosporins, carbapenems, aminoglycosides, fluoroquinolones and newer β-lactam/β-lactamase inhibitors. All isolates were susceptible to FEP/ZID and were treated with the same for 2-6 weeks. Clinico-radiographic assessments confirmed significant resolution of lesions in all cases. There were with no drug-related adverse events.</p><p><strong>Conclusion: </strong>The in-vitro susceptibility of our XDR PsA isolates to FEP/ZID translated to a successful clinical outcome in our series of deep-seated infections. FEP/ZID is a potential safe and effective treatment option for such serious Gram-negative infections.</p>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of global antimicrobial resistance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jgar.2025.07.009","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: There is a paucity of safe and effective treatment options for extensively drug resistant (XDR) Gram-negative pathogens that often harbor varied resistance mechanisms concurrently. Cefepime/zidebactam (FEP/ZID) is a novel β-lactam/β-lactam enhancer (BL-BLE) combination, currently in Phase 3 trials, that has been shown to be effective against such difficult to treat resistant isolates in in-vitro studies and scattered case reports. We present a series of deep seated infections due to XDR Pseudomonas Aeruginosa (PsA), successfully treated with FEP/ZID under compassionate use.
Method: Between September 2023 and May 2024, using clinico-radiographic and microbiologic (phenotypic drug susceptibility and whole genome sequencing) data, we identified five XDR PsA related infections that could not be safely treated with currently available antibiotics. All patients received FEP/ZID after obtaining informed consent and necessary approvals.
Results: Four cases involved osteoarticular disease while the fifth was an endovascular graft infection. Clinical specimens yielded XDR PsA isolates that harbored varied (enzymatic and non-enzymatic) resistance mechanisms to anti-pseudomonal cephalosporins, carbapenems, aminoglycosides, fluoroquinolones and newer β-lactam/β-lactamase inhibitors. All isolates were susceptible to FEP/ZID and were treated with the same for 2-6 weeks. Clinico-radiographic assessments confirmed significant resolution of lesions in all cases. There were with no drug-related adverse events.
Conclusion: The in-vitro susceptibility of our XDR PsA isolates to FEP/ZID translated to a successful clinical outcome in our series of deep-seated infections. FEP/ZID is a potential safe and effective treatment option for such serious Gram-negative infections.
期刊介绍:
The Journal of Global Antimicrobial Resistance (JGAR) is a quarterly online journal run by an international Editorial Board that focuses on the global spread of antibiotic-resistant microbes.
JGAR is a dedicated journal for all professionals working in research, health care, the environment and animal infection control, aiming to track the resistance threat worldwide and provides a single voice devoted to antimicrobial resistance (AMR).
Featuring peer-reviewed and up to date research articles, reviews, short notes and hot topics JGAR covers the key topics related to antibacterial, antiviral, antifungal and antiparasitic resistance.